Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
N Engl J Med
    April 2024
  1. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    >> Share

  2. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    >> Share

  3. VAZQUEZ MA, Oliver G, Amarasingham R, Sundaram V, et al
    Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.
    N Engl J Med. 2024;390:1196-1206.
    >> Share

    March 2024
  4. HUGHES MS, Addala A, Buckingham B
    Digital Technology for Diabetes. Reply.
    N Engl J Med. 2024;390:963-964.
    >> Share

  5. BERG TJ
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:963.
    >> Share

  6. TUMMINIA A, Gullo D, Frasca F
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962-963.
    >> Share

  7. KINNY-KOSTER B, Michalski CW, Loos M
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962.
    >> Share

    February 2024
  8. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    >> Share

  9. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    >> Share

  10. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    >> Share

  11. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    >> Share

  12. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    >> Share

  13. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    >> Share

  14. SCHWARTZ AL
    SGLT2 Inhibitors and False Positive Toxicology Tests.
    N Engl J Med. 2024;390:573-574.
    >> Share

    January 2024
  15. DANDONA P, Chaudhuri A, Ghanim H
    More on Semaglutide in Early Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:292.
    >> Share

  16. GAGLIA JL, Laffel LM, Patti ME
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    >> Share

  17. WEINRAUCH LA, D'Elia JA
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    >> Share

  18. DEVRIES JH
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:290.
    >> Share

  19. LEE TTM, Bergford S, Murphy HR
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:184.
    >> Share

  20. GRZYCH G, Kim I
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183-184.
    >> Share

  21. VIVANTI AJ, Benachi A, Voican A
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183.
    >> Share

  22. LIU MJ, Li J
    Necrobiosis Lipoidica.
    N Engl J Med. 2024;390:70.
    >> Share

    December 2023
  23. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    >> Share

  24. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    >> Share

  25. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    >> Share

  26. LUDVIGSSON J
    Immune Interventions at Onset of Type 1 Diabetes - Finally, a Bit of Hope.
    N Engl J Med. 2023;389:2199-2201.
    >> Share

  27. WAIBEL M, Wentworth JM, So M, Couper JJ, et al
    Baricitinib and beta-Cell Function in Patients with New-Onset Type 1 Diabetes.
    N Engl J Med. 2023;389:2140-2150.
    >> Share

    November 2023
  28. HUGHES MS, Addala A, Buckingham B
    Digital Technology for Diabetes.
    N Engl J Med. 2023;389:2076-2086.
    >> Share

  29. VIVANTE A, Tan W, Harrington SG, Udler MS, et al
    Case 36-2023: A 19-Year-Old Man with Diabetes and Kidney Cysts.
    N Engl J Med. 2023;389:1993-2003.
    >> Share

  30. NEWELL-PRICE J
    Testing for Arginine Vasopressin Deficiency.
    N Engl J Med. 2023;389:1920-1921.
    >> Share

  31. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    >> Share

    October 2023
  32. ROSENSTOCK J, Gowda A, Liang B
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Reply.
    N Engl J Med. 2023;389:1533.
    >> Share

  33. MISBIN RI
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023;389:1532-1533.
    >> Share

  34. SUGIYAMA K
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023;389:1532.
    >> Share

  35. ABEL ED, Ingelfinger JR, Linhales Barker S, Peek M, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 4: Understanding Old and New Therapies for Diabetes.
    N Engl J Med. 2023;389:e31.
    >> Share

  36. RAMOS EL, Dayan CM, Chatenoud L, Sumnik Z, et al
    Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
    N Engl J Med. 2023 Oct 18. doi: 10.1056/NEJMoa2308743.
    >> Share

  37. LEE TTM, Collett C, Bergford S, Hartnell S, et al
    Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMoa2303911.
    >> Share

  38. GARG SK, Polsky S
    Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMe2310798.
    >> Share

  39. ABEL ED, Ingelfinger JR, Linhales Barker S, Lopez D, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 3: Fostering Patient Engagement and Lifestyle Modifications.
    N Engl J Med. 2023;389:e27.
    >> Share

    September 2023
  40. ABEL ED, Ingelfinger JR, Kolko J, Linhales Barker S, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 2: After the Diagnosis - Making a Plan and Addressing Social Determinants of Health.
    N Engl J Med. 2023;389:e23.
    >> Share

  41. DANDONA P, Chaudhuri A, Ghanim H
    Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2023;389:958-959.
    >> Share

  42. ABEL ED, Giffin J, Ingelfinger JR, Peek M, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 1: Understanding and Preventing Type 2 Diabetes.
    N Engl J Med. 2023;389:e18.
    >> Share

    August 2023
  43. ALI ZA, Landmesser U, Maehara A, Matsumura M, et al
    Optical Coherence Tomography-Guided versus Angiography-Guided PCI.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2305861.
    >> Share

  44. MAGNUSSEN C, Ojeda FM, Leong DP, Alegre-Diaz J, et al
    Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2206916.
    >> Share

  45. KRISCHER JP, Lernmark A, Hagopian WA, Rewers MJ, et al
    SARS-CoV-2 - No Increased Islet Autoimmunity or Type 1 Diabetes in Teens.
    N Engl J Med. 2023;389:474-475.
    >> Share

    June 2023
  46. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    >> Share

  47. ROSENSTOCK J, Bain SC, Gowda A, Jodar E, et al
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023 Jun 24. doi: 10.1056/NEJMoa2303208.
    >> Share

  48. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    >> Share

  49. LINCOFF AM, Bhasin S, Flevaris P, Mitchell LM, et al
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023 Jun 16. doi: 10.1056/NEJMoa2215025.
    >> Share

  50. WADWA RP, Beck RW, Breton MD
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. Reply.
    N Engl J Med. 2023;388:2206-2207.
    >> Share

  51. SHIBUE K
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:2206.
    >> Share

  52. HSU NC, Hsu CH
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:2205-2206.
    >> Share

  53. SANTORO A, Kahn BB
    Adipocyte Regulation of Insulin Sensitivity and the Risk of Type 2 Diabetes.
    N Engl J Med. 2023;388:2071-2085.
    >> Share

    May 2023
  54. GREENE MF
    Early versus Second-Trimester Screening and Treatment for Diabetes in Pregnancy.
    N Engl J Med. 2023 May 5. doi: 10.1056/NEJMe2304543.
    >> Share

  55. SIMMONS D, Immanuel J, Hague WM, Teede H, et al
    Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.
    N Engl J Med. 2023 May 5. doi: 10.1056/NEJMoa2214956.
    >> Share

    March 2023
  56. WEGHUBER D, Kelly AS, Arslanian S
    Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    N Engl J Med. 2023;388:1146.
    >> Share

  57. MALOZOWSKI S
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145-1146.
    >> Share

  58. SNAITH JR, Greenfield JR
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145.
    >> Share

  59. BRUTTOMESSO D
    Technology in the Changing Management of Diabetes in Children.
    N Engl J Med. 2023;388:1052-1054.
    >> Share

  60. WADWA RP, Reed ZW, Buckingham BA, DeBoer MD, et al
    Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:991-1001.
    >> Share

    January 2023
  61. RUSSELL SJ, Damiano ER, Calhoun P
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. Reply.
    N Engl J Med. 2023;388:380-382.
    >> Share

  62. KHOO TK
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    N Engl J Med. 2023;388:380.
    >> Share

  63. MURATA Y, Takita M, Kami M
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    N Engl J Med. 2023;388:380.
    >> Share

    November 2022
  64. BURNSIDE MJ, Williman JA, de Bock MI
    Open-Source Automated Insulin Delivery in Type 1 Diabetes. Reply.
    N Engl J Med. 2022;387:2007-2008.
    >> Share

  65. SCARAMUZZA AE, Cherubini V, Rabbone I
    Open-Source Automated Insulin Delivery in Type 1 Diabetes.
    N Engl J Med. 2022;387:2006-2007.
    >> Share

  66. MURATA Y, Takita M, Kami M
    Open-Source Automated Insulin Delivery in Type 1 Diabetes.
    N Engl J Med. 2022;387:2006.
    >> Share

  67. DAS PRADHAN A, Glynn RJ, Fruchart JC, MacFadyen JG, et al
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2210645.
    >> Share

  68. HERRINGTON WG, Staplin N, Wanner C, Green JB, et al
    Empagliflozin in Patients with Chronic Kidney Disease.
    N Engl J Med. 2022 Nov 4. doi: 10.1056/NEJMoa2204233.
    >> Share

  69. CROWTHER CA, Tran T
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes. Reply.
    N Engl J Med. 2022;387:1720-1721.
    >> Share

  70. MOHAN V, Unnikrishnan R, Anjana RM
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1720.
    >> Share

  71. RHOADS GG
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1719-1720.
    >> Share

  72. SMITH GCS, Sovio U
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1719.
    >> Share

  73. PAINTER RC, van Rijn BB, Bossuyt PMM
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1718-1719.
    >> Share

    October 2022
  74. ARSLANIAN SA, Cox D
    Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes. Reply.
    N Engl J Med. 2022;387:1530-1531.
    >> Share

  75. SENOO Y, Kami M
    Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes.
    N Engl J Med. 2022;387:1529-1530.
    >> Share

  76. TUTTLE KR, Jones CR, Daratha KB, Koyama AK, et al
    Incidence of Chronic Kidney Disease among Adults with Diabetes, 2015-2020.
    N Engl J Med. 2022;387:1430-1431.
    >> Share

  77. LEELARATHNA L, Evans ML, Neupane S, Rayman G, et al
    Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes.
    N Engl J Med. 2022 Oct 5. doi: 10.1056/NEJMoa2205650.
    >> Share

    September 2022
  78. SHERR J
    Seeking Simpler Solutions with Diabetes Technology.
    N Engl J Med. 2022;387:1228-1229.
    >> Share

  79. RUSSELL SJ, Beck RW, Damiano ER, El-Khatib FH, et al
    Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    N Engl J Med. 2022;387:1161-1172.
    >> Share

  80. RYDEN L, Standl E
    After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk.
    N Engl J Med. 2022;387:1136-1138.
    >> Share

  81. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    N Engl J Med. 2022;387:1075-1088.
    >> Share

  82. NATHAN DM, Lachin JM, Balasubramanyam A, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    N Engl J Med. 2022;387:1063-1074.
    >> Share

  83. BROWN SA
    On the Path toward Expanding Treatment Options for Diabetes.
    N Engl J Med. 2022;387:935-936.
    >> Share

  84. BOUGHTON CK, Allen JM, Ware J, Wilinska ME, et al
    Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.
    N Engl J Med. 2022;387:882-893.
    >> Share

  85. BURNSIDE MJ, Lewis DM, Crocket HR, Meier RA, et al
    Open-Source Automated Insulin Delivery in Type 1 Diabetes.
    N Engl J Med. 2022;387:869-881.
    >> Share

  86. BOLINDER J
    CLOuDs Disperse - Top-Notch Glucose Control and Residual C-Peptide Secretion.
    N Engl J Med. 2022;387:937-938.
    >> Share

    August 2022
  87. SOLOMON SD, McMurray JJV, Claggett B, de Boer RA, et al
    Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2206286.
    >> Share

  88. CROWTHER CA, Samuel D, McCowan LME, Edlin R, et al
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:587-598.
    >> Share

  89. LESLIE BR, Gerwin LE
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:478.
    >> Share

  90. HEYMAN SN, Abassi Z
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:477-478.
    >> Share

    July 2022
  91. MUSCH DC, Chew EY
    Evidence for Step Therapy in Diabetic Macular Edema.
    N Engl J Med. 2022 Jul 14. doi: 10.1056/NEJMe2208454.
    >> Share

  92. JHAVERI CD, Glassman AR, Ferris FL 3rd, Liu D, et al
    Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
    N Engl J Med. 2022 Jul 14. doi: 10.1056/NEJMoa2204225.
    >> Share

    June 2022
  93. ARSLANIAN SA, Hannon T, Zeitler P, Chao LC, et al
    Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2204601.
    >> Share

  94. JASTREBOFF AM, Aronne LJ, Ahmad NN, Wharton S, et al
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2206038.
    >> Share

    May 2022
  95. BRAUNWALD E
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;386:2024-2034.
    >> Share

    April 2022
  96. PITT B, Joseph A, Schloemer P
    Cardiovascular Events with Finerenone in CKD and Diabetes. Reply.
    N Engl J Med. 2022;386:e43.
    >> Share

  97. ORTIZ A, Sarafidis P, Ferro CJ
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    >> Share

  98. GERARD AO, Laurain A, Esnault VLM
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    >> Share

  99. KAO PH, Hsu LC
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    >> Share

  100. WARE J, Hovorka R
    Closed-Loop Control in Very Young Children with Type 1 Diabetes. Reply.
    N Engl J Med. 2022;386:1482-1483.
    >> Share

  101. RING BL
    Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    N Engl J Med. 2022;386:1482.
    >> Share

  102. MURATA Y, Takita M, Kami M
    Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    N Engl J Med. 2022;386:1482.
    >> Share

    March 2022
  103. SPERLING MA, Laffel LM
    Current Management of Glycemia in Children with Type 1 Diabetes Mellitus.
    N Engl J Med. 2022;386:1155-1164.
    >> Share

    February 2022
  104. WING JR, Kimball A, Rengarajan M
    Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.
    N Engl J Med. 2022;386:781-787.
    >> Share

  105. FRIAS JP, Fernandez Lando L, Brown K
    Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
    N Engl J Med. 2022;386:e17.
    >> Share

  106. SANTULLI G
    Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
    N Engl J Med. 2022;386:e17.
    >> Share

  107. PATOULIAS D, Papadopoulos C, Doumas M
    Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
    N Engl J Med. 2022;386:e17.
    >> Share

    January 2022
  108. WARE J, Allen JM, Boughton CK, Wilinska ME, et al
    Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    N Engl J Med. 2022;386:209-219.
    >> Share

  109. DRAIN PK
    Rapid Diagnostic Testing for SARS-CoV-2.
    N Engl J Med. 2022 Jan 7. doi: 10.1056/NEJMcp2117115.
    >> Share

    November 2021
  110. GERSTEIN HC, Khurmi NS
    Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. Reply.
    N Engl J Med. 2021;385:2107.
    >> Share

  111. HE L, Zhang H
    Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;385:2106-2107.
    >> Share

  112. GROOTHOF D, Vogelpohl FA, Bakker SJL
    Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;385:2106.
    >> Share

  113. BORDERIE G, Schnebelen M, Baynat L
    Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;385:2105-2106.
    >> Share

  114. O'CONNELL J, Nathan DM, O'Brien T, O'Keeffe DT, et al
    Treatment of Diabetes - To Pump or Not to Pump.
    N Engl J Med. 2021;385:2092-2095.
    >> Share

  115. BJORNSTAD P, Drews K, Zeitler PS
    Long-Term Complications in Youth-Onset Type 2 Diabetes. Reply.
    N Engl J Med. 2021;385:2016.
    >> Share

  116. NELSON RG, Hanson RL, Knowler WC
    Long-Term Complications in Youth-Onset Type 2 Diabetes.
    N Engl J Med. 2021;385:2015.
    >> Share

  117. YANG W, Wang C
    Long-Term Complications in Youth-Onset Type 2 Diabetes.
    N Engl J Med. 2021;385:2014-2015.
    >> Share

    October 2021
  118. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021;385:1547-1558.
    >> Share

    August 2021
  119. PACKER M, Butler J, Zannad F, Pocock SJ, et al
    Empagliflozin and Major Renal Outcomes in Heart Failure.
    N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMc2112411.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016